Haga, K.; Shibuya, T.; Osada, T.; Sato, S.; Fukuo, Y.; Kobayashi, O.; Yamada, T.; Asaoka, D.; Ito, K.; Nomura, K.;
et al. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. Biomedicines 2022, 10, 2526.
https://doi.org/10.3390/biomedicines10102526
AMA Style
Haga K, Shibuya T, Osada T, Sato S, Fukuo Y, Kobayashi O, Yamada T, Asaoka D, Ito K, Nomura K,
et al. Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. Biomedicines. 2022; 10(10):2526.
https://doi.org/10.3390/biomedicines10102526
Chicago/Turabian Style
Haga, Keiichi, Tomoyoshi Shibuya, Taro Osada, Shunsuke Sato, Yuka Fukuo, Osamu Kobayashi, Toshio Yamada, Daisuke Asaoka, Kentaro Ito, Kei Nomura,
and et al. 2022. "Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis" Biomedicines 10, no. 10: 2526.
https://doi.org/10.3390/biomedicines10102526
APA Style
Haga, K., Shibuya, T., Osada, T., Sato, S., Fukuo, Y., Kobayashi, O., Yamada, T., Asaoka, D., Ito, K., Nomura, K., Haraikawa, M., Nomura, O., Fukushima, H., Murakami, T., Ishikawa, D., Hojo, M., & Nagahara, A.
(2022). Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis. Biomedicines, 10(10), 2526.
https://doi.org/10.3390/biomedicines10102526
